阿扎胞苷联合CAG方案治疗急性髓系白血病患者的临床效果  

Clinical effect of azacitidine combined with CAG regimen in the treatment of patients with acute myeloid leukemia

作　　者：夏庆斌 武玉慧 宋岭 XIA Qingbin;WU Yuhui;SONG Ling(Hematology Department,Xinyang Central Hospital,Xinyang 464000,China)

机构地区：[1]信阳市中心医院血液内科,河南信阳464000

出　　处：《临床医学研究与实践》2024年第35期38-41,共4页Clinical Research and Practice

摘　　要：目的探讨阿扎胞苷联合CAG方案(阿柔比星+阿糖胞苷+粒细胞集落刺激因子)治疗急性髓系白血病患者的临床效果。方法选取2020年1月至2023年6月信阳市中心医院收治的68例急性髓系白血病患者为研究对象,以随机数字表法将其分为对照组和观察组,各34例。对照组采用CAG方案治疗,观察组在对照组基础上联合阿扎胞苷治疗。比较两组的治疗效果。结果观察组的治疗总有效率显著高于对照组,差异具有统计学意义(P<0.05)。治疗后,观察组的白细胞计数、血小板计数高于对照组,血红蛋白水平低于对照组,差异具有统计学意义(P<0.05)。治疗后,观察组的CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)高于对照组,CD8^(+)低于对照组(P<0.05)。治疗后,观察组的血管内皮生长因子(VEGF)、碱性成纤维细胞生长因子(bFGF)水平低于对照组,差异具有统计学意义(P<0.05)。两组的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论阿扎胞苷联合CAG方案治疗急性髓系白血病患者的临床效果显著,可改善血常规指标及免疫功能,降低VEGF、bFGF水平,安全性高。Objective To investigate the clinical effect of azacitidine combined with CAG regimen(aclarubicin+cytarabine+granulocyte colony stimulating factor)in the treatment of patients with acute myeloid leukemia.Methods A total of 68 patients with acute myeloid leukemia admitted in Xinyang Central Hospital from January 2020 to June 2023 were selected as the research objects and divided into control group and observation group by random number table method,with 34 cases in each group.The control group was treated with CAG regimen,and the observation group was treated with azacitidine on the basis of the control group.The therapeutic effects of the two groups were compared.Results The total effective rate of treatment in the observation group was significantly higher than that in the control group,the difference was statistically significant(P<0.05).After treatment,the white blood cell count and platelet count in the observation group were higher than those in the control group,and the hemoglobin level was lower than that in the control group,the differences were statistically significant(P<0.05).After treatment,the CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)in the observation group were higher than those in the control group,and the CD8^(+)was lower than that in the control group(P<0.05).After treatment,the levels of vascular endothelial growth factor(VEGF)and basic fibroblast growth factor(bFGF)in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reaction between the two groups(P>0.05).Conclusion The azacitidine combined with CAG regimen in the treatment of patients with acute myeloid leukemia has significant clinical effect.It can improve blood routine indexes and immune function,and reduce the levels of VEGF and bFGF with high safety.

关 键 词：急性髓系白血病 阿扎胞苷 阿柔比星 阿糖胞苷 粒细胞集落刺激因子 

分 类 号：R733.71[医药卫生—肿瘤]